|
|
Volumn 343, Issue , 2011, Pages
|
|
Commentary: Does additional benefit justify additional costs of insulin analogues?
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIDIABETIC AGENT;
DRUG DERIVATIVE;
INSULIN;
ARTICLE;
COST BENEFIT ANALYSIS;
DIABETES MELLITUS;
DRUG COST;
DRUG INDUSTRY;
GERMANY;
HUMAN;
COST-BENEFIT ANALYSIS;
DIABETES MELLITUS;
DRUG COSTS;
DRUG INDUSTRY;
GERMANY;
HUMANS;
HYPOGLYCEMIC AGENTS;
INSULIN;
|
|
EID: 80053017051
PISSN: None
EISSN: 14685833
Source Type: Journal
DOI: 10.1136/bmj.d5858 Document Type: Article |
|
Times cited : (3)
|
|
References (0)
|
